Unresectable pancreatic cancer
Conditions
Interventions
None listed
Sponsors
Federation of Asian Clinical Oncology (FACO)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with initially pathological confirmed adenocarcinoma and consitent with pancreatic ductal adenocarcinoma including papillary adenocarcinoma, tubular adenocarcinoma, poor differentiated adenocarcinoma, or adenosquamous carcinoma by diagnostic imaging 2. Locally advanced or distant metastatic disease before starting of chemotherapy 3. FOLFIRINOX (including modified regimen) or gemcitabine plus nab-paclitaxel initially performed 4. Diagnosed as resectable disease after chemotherapy by imaging, then laparotomy or continuation of chemotherapy performed
Exclusion criteria
Exclusion criteria: 1. Borderline resectable disease by NCCN Guidelines Ver 2.2018 is excluded in this study. Solid tumor contact with the CA >180 degrees is classified to unrsectable. 2. Recurrent disease 3. Response to chemotherapy according to RECIST ver 1.1 was PD 4. Heavy ion radiotherapy or proton beam therapy performed before laparotomy 5. Diagnosed as unresectable disease by examination laparoscopic when was intented to conversion surgery 6. Resection of metastatic lesions at conversion surgery. However, patients can be registered unless they are pathologically demonstrated to have cancer after dissection of the 16th lymph node or hepatectomy. 7. Peritoneal lavage cytology positive
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival from the day when resection was considered to be possible (day of examination) | — |
Secondary
| Measure | Time frame |
|---|---|
| Relapse-free survival, post-resection survival, mode of relapse, presence or absence of hospital death, and surgery-related complications | — |
Countries
Japan,Asia(except Japan)
Contacts
Public ContactMami Sakurai
Federation of Asian Clinical Oncology (FACO) Tokyo Office
Outcome results
None listed